Adaptimmune Short Term Debt vs Total Liab Analysis
ADAP Stock | USD 1.04 0.02 1.96% |
Adaptimmune Therapeutics financial indicator trend analysis is way more than just evaluating Adaptimmune Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Adaptimmune Therapeutics is a good investment. Please check the relationship between Adaptimmune Therapeutics Short Term Debt and its Total Liab accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adaptimmune Therapeutics Plc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
Short Term Debt vs Total Liab
Short Term Debt vs Total Liab Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Adaptimmune Therapeutics Short Term Debt account and Total Liab. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Adaptimmune Therapeutics' Short Term Debt and Total Liab is -0.21. Overlapping area represents the amount of variation of Short Term Debt that can explain the historical movement of Total Liab in the same time period over historical financial statements of Adaptimmune Therapeutics Plc, assuming nothing else is changed. The correlation between historical values of Adaptimmune Therapeutics' Short Term Debt and Total Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Short Term Debt of Adaptimmune Therapeutics Plc are associated (or correlated) with its Total Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Liab has no effect on the direction of Short Term Debt i.e., Adaptimmune Therapeutics' Short Term Debt and Total Liab go up and down completely randomly.
Correlation Coefficient | -0.21 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Short Term Debt
Total Liab
The total amount of all liabilities that a company has, including both short-term and long-term liabilities.Most indicators from Adaptimmune Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Adaptimmune Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adaptimmune Therapeutics Plc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. As of 06/12/2024, Selling General Administrative is likely to drop to about 37.2 M. In addition to that, Tax Provision is likely to drop to about 832.7 K
2021 | 2022 | 2023 | 2024 (projected) | Net Interest Income | 1.1M | 1.5M | 6.0M | 6.3M | Interest Income | 1.1M | 1.5M | 6.0M | 6.3M |
Adaptimmune Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Adaptimmune Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Adaptimmune Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 181.5M | 451.1M | 469.5M | 328.9M | 282.6M | 268.1M | |
Other Current Liab | 23.4M | 27.1M | 29.9M | 33.5M | 30.3M | 21.7M | |
Total Current Liabilities | 34.3M | 39.1M | 62.5M | 64.5M | 72.8M | 44.6M | |
Total Stockholder Equity | 123.6M | 341.2M | 206.0M | 81.9M | 39.5M | 37.5M | |
Property Plant And Equipment Net | 51.9M | 46.7M | 51.4M | 71.5M | 71.7M | 75.3M | |
Net Debt | (25.0M) | (33.2M) | (124.5M) | (85.0M) | (118.8M) | (112.8M) | |
Retained Earnings | (455.7M) | (585.8M) | (743.8M) | (909.3M) | (1.0B) | (972.0M) | |
Accounts Payable | 6.4M | 6.4M | 8.1M | 4.8M | 8.1M | 5.5M | |
Cash | 50.4M | 56.9M | 149.9M | 108.0M | 144.0M | 112.8M | |
Non Current Assets Total | 61.1M | 53.0M | 54.1M | 73.5M | 75.1M | 39.1M | |
Other Assets | 7.0M | 4.6M | 1.7M | 1.6M | 1.8M | 1.7M | |
Cash And Short Term Investments | 89.5M | 368.2M | 369.6M | 204.6M | 146.9M | 202.8M | |
Net Receivables | (1.5M) | 139K | 752K | 7.4M | 46.9M | 49.3M | |
Common Stock Total Equity | 939K | 943K | 1.3M | 1.3M | 1.5M | 1.6M | |
Liabilities And Stockholders Equity | 181.5M | 451.1M | 469.5M | 328.9M | 282.6M | 268.1M | |
Non Current Liabilities Total | 23.6M | 70.8M | 201.0M | 182.5M | 170.3M | 178.8M | |
Other Current Assets | 30.9M | 29.8M | 45.1M | 43.3M | 13.7M | 19.3M | |
Other Stockholder Equity | 585.6M | 935.7M | 959.6M | 990.7M | 1.1B | 535.2M | |
Total Liab | 57.9M | 109.9M | 263.6M | 247.0M | 243.1M | 255.3M | |
Property Plant And Equipment Gross | 51.9M | 46.7M | 51.4M | 71.5M | 130.9M | 137.5M | |
Total Current Assets | 120.5M | 398.2M | 415.5M | 255.4M | 207.6M | 229.0M | |
Accumulated Other Comprehensive Income | (7.3M) | (10.0M) | (11.1M) | (875K) | (3.7M) | (3.6M) | |
Common Stock | 943K | 1.3M | 1.3M | 1.4M | 1.9M | 2.0M | |
Short Long Term Debt Total | 25.5M | 23.7M | 25.5M | 23.1M | 25.2M | 38.5M | |
Common Stock Shares Outstanding | 105.0M | 142.5M | 155.8M | 161.2M | 201.1M | 129.5M | |
Property Plant Equipment | 31.1M | 27.8M | 30.5M | 71.5M | 82.3M | 86.4M | |
Net Tangible Assets | 121.4M | 339.5M | 205.0M | 81.4M | 93.7M | 89.0M | |
Non Currrent Assets Other | 7.0M | 4.6M | 1.7M | 1.6M | 3.0M | 3.6M | |
Short Term Investments | 39.1M | 311.3M | 219.6M | 96.6M | 2.9M | 2.8M | |
Other Liab | 598K | 49.9M | 177.9M | 162.2M | 186.5M | 195.8M | |
Inventory | 1.5M | 2.1M | 746K | 1.3M | 1.3M | 1.4M | |
Intangible Assets | 2.2M | 1.7M | 1M | 442K | 330K | 313.5K | |
Capital Surpluse | 574.2M | 585.6M | 935.7M | 959.6M | 1.1B | 657.5M | |
Retained Earnings Total Equity | (318.5M) | (455.7M) | (585.8M) | (743.8M) | (669.5M) | (636.0M) | |
Non Current Liabilities Other | 23.6M | 70.8M | 201.0M | 1.3M | 1.4M | 1.3M | |
Net Invested Capital | 123.6M | 341.2M | 206.0M | 81.9M | 39.5M | 37.5M | |
Net Working Capital | 86.1M | 359.1M | 352.9M | 190.9M | 134.8M | 233.6M | |
Capital Stock | 943K | 1.3M | 1.3M | 1.4M | 1.9M | 1.4M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectAdditional Tools for Adaptimmune Stock Analysis
When running Adaptimmune Therapeutics' price analysis, check to measure Adaptimmune Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptimmune Therapeutics is operating at the current time. Most of Adaptimmune Therapeutics' value examination focuses on studying past and present price action to predict the probability of Adaptimmune Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptimmune Therapeutics' price. Additionally, you may evaluate how the addition of Adaptimmune Therapeutics to your portfolios can decrease your overall portfolio volatility.